Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma

Clinical Cancer Research

Volumn 18, Issue 2, 2012, Pages 408-416

  Landreville, Solange ^a   Agapova, Olga A ^a   Matatall, Katie A ^a   Kneass, Zachary T ^a   Onken, Michael D ^a   Lee, Ryan S ^a   Bowcock, Anne M ^a   Harbour, J William ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAP1 GENE; CANCER ADJUVANT THERAPY; CANCER INHIBITION; CANCER PREVENTION; CARCINOGENICITY; CELL CYCLE ARREST; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOSS; HISTONE ACETYLATION; HISTONE UBIQUITINATION; IN VIVO STUDY; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; TRANSCRIPTOMICS; TREATMENT DURATION; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMORADIOTHERAPY, ADJUVANT; COMPUTER SIMULATION; GENE KNOCKDOWN TECHNIQUES; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; MODELS, BIOLOGICAL; NEOPLASM MICROMETASTASIS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS; VALPROIC ACID; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84856023489     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0946     Document Type: Article

References (30)

1. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. APMIS 2008;116:754-70.
2. Landreville S, Agapova OA, Harbour JW. Emerging insights into the molecular pathogenesis of uveal melanoma. Future Oncol 2008;4:629-36.
3. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC. Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol 2005;89:1270-4. (Pubitemid 41638863)
4. Onken MD, Worley LA, Tuscan MD, Harbour JW. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12:461-8.
5. Chang SH, Worley LA, Onken MD, Harbour JW. Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 2008;18:191-200. (Pubitemid 351684664)
6. Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-3.
7. Jensen DE, Proctor M, Marquis ST, Gardner HP, Ha SI, Chodosh LA, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-112. (Pubitemid 28127509)
8. Ventii KH, Devi NS, Friedrich KL, Chernova TA, Tighiouart M, Van Meir EG, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008;68:6953-62.
9. Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, et al. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 2011 Sep 22. [Epub ahead of print].
10. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 2011;43:1022-5.
11. Wiesner T, Obenauf AC, Murali R, Fried I, Griewank KG, Ulz P, et al. Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet 2011;43:1018-21.
12. Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW. Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma. Clin Cancer Res 2007;13:2923-7. (Pubitemid 46849567)
13. Landreville S, Agapova OA, Kneass ZT, Salesse C, Harbour JW. ABCB1 identifies a subpopulation of uveal melanoma cells with high metastatic propensity. Pigment Cell Melanoma Res 2011;24:430-7.
14. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007;318:1108-13. (Pubitemid 350134889)
15. Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-9. (Pubitemid 39372052)
16. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005;102:15545-50. (Pubitemid 41528093)
17. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006;313:1929-35. (Pubitemid 44497995)
18. Delston RB, Matatall KA, Sun Y, Onken MD, Harbour JW. p38 phosphorylates Rb on Ser567 by a novel, cell cycle-independentmechanism that triggers Rb-Hdm2 interaction and apoptosis. Oncogene 2011;30:588-99.
19. Stewart SA, Dykxhoorn DM, Palliser D, Mizuno H, Yu EY, An DS, et al. Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA 2003;9:493-501. (Pubitemid 36356735)
20. Shechter D, Dormann HL, Allis CD, Hake SB. Extraction, purification and analysis of histones. Nat Protoc 2007;2:1445-57. (Pubitemid 46952324)
21. Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, Marks PA, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005;102:3697-702. (Pubitemid 40354674)
22. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010;465:243-7.
23. Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar JD, Dimri GP. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 2010;9:2663-73.
24. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-78. (Pubitemid 34062289)
25. van Leeuwen F, van Steensel B. Histone modifications: from genomewide maps to functional insights. Genome Biol 2005;6:113.
26. de Napoles M, Mermoud JE, Wakao R, Tang YA, Endoh M, Appanah R, et al. Polycomb group proteins Ring1A/B link ubiquitylation of histone H2A to heritable gene silencing and X inactivation. Dev Cell 2004;7:663-76. (Pubitemid 39462687)
27. Wang H, Wang L, Erdjument-Bromage H, Vidal M, Tempst P, Jones RS, et al. Role of histone H2A ubiquitination in Polycomb silencing. Nature 2004;431:873-8. (Pubitemid 39434086)
28. Zhu P, Zhou W, Wang J, Puc J, Ohgi KA, Erdjument-Bromage H, et al.A histone H2A deubiquitinase complex coordinating histone acetylation and H1 dissociation in transcriptional regulation. Mol Cell 2007;27:609-21. (Pubitemid 47238636)
29. Tan J, Cang S, Ma Y, Petrillo RL, Liu D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.
30. Rocca A, Minucci S, Tosti G, Croci D, Contegno F, Ballarini M, et al. A phase I-II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. Br J Cancer 2009;100:28-36.